SHATTUCK LABS INC

Shattuck Labs’ disciplined insider trading shows executives prioritizing tax efficiency, liquidity, and compliance, positioning the biotech for stable growth and favorable payer negotiations.

Shattuck Labs’ June 11 public offering and insider buys aim to fund its Phase 2b SL‑325 trial, boost RWE and digital‑health data, and strengthen its capital base for value‑based reimbursement opportunities.

OrbiMed’s $15 million pre‑funded warrant purchase at Shattuck Labs signals bullish institutional confidence ahead of SL‑325 Phase 1 data, offering high‑risk upside and immediate liquidity for investors.

CEO Schreiber Taylor’s fresh share buy at Shattuck Labs signals strong insider confidence ahead of SL‑325 Phase 2 data—potential upside for investors.